For Industry

Public Meeting on Pulmonary Arterial Hypertension Patient-Focused Drug Development

On May 13, 2014, FDA conducted a public meeting on Pulmonary Arterial Hypertension Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of pulmonary arterial hypertension on daily life and patients’ views on currently available therapies to treat the condition.

This website will be updated as meeting materials are developed.  

Date:May 13, 2014
Time:1:00 p.m. to 5:00 p.m.
Location:FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A  (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)                
To register for this meeting, visit:
Registration closed on April 30, 2014

Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 14, 2014.

Webcast Recording


Page Last Updated: 01/20/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English